Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-30
2005-08-30
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S184000
Reexamination Certificate
active
06936609
ABSTRACT:
The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.
REFERENCES:
patent: 3941785 (1976-03-01), Clarke et al.
patent: 2811780 (1978-09-01), None
patent: 9924433 (1999-05-01), None
patent: 0124781 (2001-04-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Lucas et al. Pharmacological Reviews 52 (3), 375-413, 2000.
Beavo, J. A., “Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms”, Pharmacological Reviews, 75(4): 725-748 (Oct. 1995).
Beavo, J. A, Conti, M., and Heaslip, R. J., “Multiple Cyclic Nucleotide Phosphodiesterases”, Molecular Pharmacology, 46(3): 399-405 (Sep. 1994).
Charles, I., Latham, D. W. S., Hartley, D., Oxford, A. W., and Scopes, D. I. C., “Bicyclic Heterocycles with Nitrogen at the Ring Junction. Part 2. 1. Application of the Dakin-West Reaction to the Synthesis of Immidazo-[5,1-f]-1,2,4-triazin-4-(3H)-ones”, J. Chem. Soc., Perkin Trans. I, 5(1): 1139-1146 (May 1980).
Soderling, S. H., and Beavo, J. A., “Regulation of cAMP and cGMP Signaling: New Phosphodiesterases and New Functions”, Current Opinion in Cell Biology, 12(2): 174-179 (Apr. 2000).
Bauser Marcus
Brückner David
Burkhardt Nils
Ergüden Jens-Kerim
Flubacher Dietmar
Balasubramanian Venkataraman
Bayer HealthCare AG
Pellegrino Susan M.
LandOfFree
Imidazotriazines for use as phosphodiesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazotriazines for use as phosphodiesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazotriazines for use as phosphodiesterase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468030